Literature DB >> 10698090

Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue.

E E Diehl1, G K Haines, J A Radosevich, L A Potempa.   

Abstract

BACKGROUND: The prototypic acute phase reactant, C-reactive protein (CRP), is a serum soluble, cyclic pentameric protein, the concentration of which increases markedly within hours of any tissue-damaging, inflammatory event. However, upon dissociation of its pentameric quaternary structure, CRP subunits undergo a spontaneous and irreversible conformational change. The resulting molecule, termed modified CRP or mCRP, has reduced aqueous solubility and a propensity to aggregate into a matrix-like lattice structure.
METHODS: Using monoclonal antibodies, normal human tissues were immunohistochemically screened for the presence of CRP as well as mCRP antigens.
RESULTS: Significant levels of mCRP were detected in the walls of blood vessels associated with normal human tissues. These data indicate that mCRP is a naturally occurring form of CRP and that it is a tissue-based rather than serum-based molecule. SIGNIFICANCE: This report describes the localization of a stable form of CRP, mCRP, in blood vessels associated with normal human tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698090     DOI: 10.1097/00000441-200002000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  30 in total

1.  C-reactive protein in vulnerable coronary plaques.

Authors:  Silja Norja; Lauri Nuutila; Pekka J Karhunen; Sirkka Goebeler
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?

Authors:  Sean G O'Neill; David A Isenberg; Anisur Rahman
Journal:  Ann Rheum Dis       Date:  2007-08       Impact factor: 19.103

3.  C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1.

Authors:  Keiji Tanigaki; Chieko Mineo; Ivan S Yuhanna; Ken L Chambliss; Michael J Quon; Ezio Bonvini; Philip W Shaul
Journal:  Circ Res       Date:  2009-05-07       Impact factor: 17.367

4.  Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; David J Hammond; Antonio E Rusiñol; Lawrence A Potempa; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2009-06-21       Impact factor: 3.786

5.  C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP.

Authors:  Min S Wang; Joshua C Black; Michelle K Knowles; Scott M Reed
Journal:  Anal Bioanal Chem       Date:  2011-07-02       Impact factor: 4.142

6.  Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide.

Authors:  Reiko T Lee; Yuan C Lee
Journal:  Glycoconj J       Date:  2006-07       Impact factor: 2.916

7.  Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses.

Authors:  Hai-Yun Li; Jing Wang; Yue-Xin Wu; Lin Zhang; Zu-Pei Liu; János G Filep; Lawrence A Potempa; Yi Wu; Shang-Rong Ji
Journal:  J Biol Chem       Date:  2014-04-07       Impact factor: 5.157

8.  C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer.

Authors:  Azubuike I Okemefuna; Lasse Stach; Sudeep Rana; Akim J Ziai Buetas; Jayesh Gor; Stephen J Perkins
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

Review 9.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

10.  C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta.

Authors:  Karen J Ho; Christopher D Owens; Thomas Longo; Xin X Sui; Cristos Ifantides; Michael S Conte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.